MedTrace Logo

Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression

NCT04136223 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-29

No results posted yet for this study

Summary

BERTHA study´s primary objective is to characterize Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) progression and to define a combination of biomarkers, genetic and clinical variables capable of identifying patients at risk of RA-ILD progression

Conditions

Sponsors & Collaborators

Principal Investigators

  • Prof. Alexandra Latini, PhD · Federal University of Santa Catarina

  • Leticia Kawano-Dourado, MD · HCOR Research Institute, Hospital do Coracao, São Paulo, Brazil

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04136223 on ClinicalTrials.gov